Form 4 for SPRO Spero Therapeutics, Inc.
Accepted 2026-05-06 21:53:26 ET · period of report 2026-05-04 · accession 0001193125-26-209884 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-06 21:53 | 2026-05-04 | SPRO | Rajavelu Esther | See Remarks | S - Sale | $2.51 | -25.2K | 986.9K | -2% | -$63.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-04 | S | D | 25,240 | $2.51 | 986,851 | D | — | — | (F1) Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. (F1) Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. |